Effect of Walking on Brain Fuel Consumption in Mild Alzheimer's Disease

NCT02708485 | Completed Results

• 1 other identifier: 09-043
• Study Type: interventional
• Target: 15
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to evaluate the effect of a 3-month walking program on brain energy metabolism in patient with mild Alzheimer's disease (AD). Two groups of sedentary patients with mild AD are followed and compared over a 3-month period of time: Control (non-active) and walking (from 15 to 45 minutes of exercise on a treadmill, 3 times a week for 12 weeks) groups. All the participants are evaluated on their cognition, brain volumes (MRI) and brain fuel consumption (PET scan with 18-FDG and 11C-AcAc) at the beginning and at the end of the study.

Conditions

Alzheimer's Disease

Outcome Measures

Primary Outcomes (2)

• Brain Glucose Consumption

  Brain glucose uptake (umol/100g/min) using 18F-FDG PET imaging

  3 months

• Brain Acetoacetate Consumption

  Brain acetoacetate uptake (umol/100g/min) using 11C-AcAc PET imaging

  3 months

Study Arms (2)

Control group

NO INTERVENTION

No intervention

Physical exercise

EXPERIMENTAL

A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).

Other: Physical exercise

Interventions

Physical exercise OTHER

A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).

Physical exercise

Eligibility Criteria

• Age: 40 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Diagnosis of mild Alzheimer's disease (NINCDS-ADRDA criteria)
• Taking cholinesterase inhibitors
• Sedentary
• Ability to do physical exercise

You may not qualify if:

• Parkinson disease
• Down syndrome
• Epilepsy or concussion
• Drug or alcohol abuse
• Past psychiatric history
• Vitamin B12 Deficiency
• Uncontrolled diabetes or thyroid function

Sponsors & Collaborators

• Université de Sherbrooke: lead

Study Sites (1)

Research Centre on Aging (CSSS-IUGS - CIUSSS de l'Estrie - CHUS)

Sherbrooke, Quebec, J1H4C4, Canada

Location

MeSH Terms

Conditions

Alzheimer Disease

Interventions

Exercise

Condition Hierarchy (Ancestors)

Dementia; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Tauopathies; Neurodegenerative Diseases; Neurocognitive Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Motor Activity; Movement; Musculoskeletal Physiological Phenomena; Musculoskeletal and Neural Physiological Phenomena

Results Point of Contact

• Title: Stephen Cunnane
• Organization: USherbrooke

Stephen.Cunnane@USherbrooke.ca

1-819-780-2220

Study Officials

• Nancy Paquet, MD

  Estrie University Integrated Health and Social Services Center - University Hospital of Sherbrooke

  PRINCIPAL INVESTIGATOR

• Stephen Cunnane, PhD

  CDRV - CSSS-IUGS - CIUSSS de l'Estrie - CHUS

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restrictive Agreement: No

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: March 10, 2016
• First Posted: March 15, 2016
• Study Start: April 1, 2009
• Primary Completion: July 1, 2017
• Study Completion: July 1, 2017
• Last Updated: October 16, 2018
• Results First Posted: October 16, 2018

Record last verified: 2017-07

Locations

CA (1)